Your browser doesn't support javascript.
loading
Real-world impact of transitioning from one lipoprotein(a) assay to another in a clinical setting.
Jeevanathan, Janeni; Blom, Sigrid M; Olsen, Thomas; Holven, Kirsten B; Arnesen, Erik K; Trydal, Torleif; Nordestgaard, Børge G; Sovershaev, Michael; Chen, Ying; Retterstøl, Kjetil; Christensen, Jacob J.
Afiliação
  • Jeevanathan J; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, 0317, Oslo, Norway.
  • Blom SM; Novartis Norway AS, Nydalen alle 37, 0484, Oslo, Norway.
  • Olsen T; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, 0317, Oslo, Norway.
  • Holven KB; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, 0317, Oslo, Norway.
  • Arnesen EK; Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital Aker, P.O. Box 4959 Nydalen, 0424, Oslo, Norway.
  • Trydal T; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, 0317, Oslo, Norway.
  • Nordestgaard BG; Department of Clinical Research, Sørlandet Hospital, SSHF, P.O. Box 416 Lundsiden, 4604, Kristiansand, Norway.
  • Sovershaev M; The Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Borgmester Ib Juuls Vej 73, opgang 7, 2730, Herlev, Denmark.
  • Chen Y; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark.
  • Retterstøl K; Fürst Medical Laboratory, P. O. Box 158 Alnabru, 0614, Oslo, Norway.
  • Christensen JJ; Fürst Medical Laboratory, P. O. Box 158 Alnabru, 0614, Oslo, Norway.
Am J Prev Cardiol ; 19: 100726, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39286651
ABSTRACT
Background and

aims:

Different lipoprotein(a) [Lp(a)] assays may affect risk stratification of individuals and thus clinical decision-making. We aimed to investigate how transitioning between Lp(a) assays at a large central laboratory affected the proportion of individuals with Lp(a) result above clinical thresholds.

Methods:

We studied nationwide clinical laboratory data including 185,493 unique individuals (47.7 % women) aged 18-50 years with 272,463 Lp(a) measurements using Roche (2000-2009) and Siemens Lp(a) assay (2009-2019).

Results:

While the majority of individuals (66-75 %) had low levels of Lp(a) (<30 mg/dL) independent of the assay used, the Roche assay detected 20 % more individuals with Lp(a) >50 mg/dL, 40 % more individuals with Lp(a) >100 mg/dL and 80 % more individuals with Lp(a) > 180 mg/dL than the currently used Siemens assay, likely due to calibration differences.

Conclusion:

Transitioning from one Lp(a) immunoassay to another had significant impact on Lp(a) results, particularly in individuals approaching clinically relevant Lp(a) thresholds.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Prev Cardiol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Noruega País de publicação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Prev Cardiol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Noruega País de publicação: Holanda